The SH2 domain: versatile signaling module and pharmaceutical target

被引:176
作者
Machida, K [1 ]
Mayer, BJ [1 ]
机构
[1] Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Raymond & Beverly Sackler Lab Genet & Mol Med, Farmington, CT 06030 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS | 2005年 / 1747卷 / 01期
关键词
protein tyrosine kinase; signal transduction; SH2; inhibitor; phosphotyrosine mimetic;
D O I
10.1016/j.bbapap.2004.10.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Src homology 2 (SH2) domain is the most prevalent protein binding module that recognizes phosphotyrosine. This similar to100-aminoacid domain is highly conserved structurally despite being found in a wide variety proteins. Depending on the nature of neighboring protein module(s), such as catalytic domains and other protein binding domains, SH2-containing proteins play many different roles in cellular protein tyrosine kinase (PTK) signaling pathways. Accumulating evidence indicates SH2 domains are highly versatile and exhibit considerable flexibility in how they bind to their ligands. To illustrate this functional versatility, we present three specific examples: the SAP, Cbl and SOCS families of SH2-containing proteins, which play key roles in immune responses, termination of PTK signaling, and cytokine responses. In addition, we highlight current progress in the development of SH2 domain inhibitors designed to antagonize or modulate PTK signaling in human disease. Inhibitors of the Grb2 and Src SH2 domains have been extensively studied, with the aim of targeting the Ras pathway and osteoclastic bone resorption, respectively. Despite formidable difficulties in drug design due to the lability and poor cell permeability of negatively charged phosphorylated SH2 ligands, a variety of structure-based strategies have been used to reduce the size, charge and peptide character of such ligands, leading to the development of high-affinity lead compounds with potent cellular activities. These studies have also led to new insights into molecular recognition by the SH2 domain. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 25
页数:25
相关论文
共 267 条
[1]   Normalization of nomenclature for peptide motifs as ligands of modular protein domains [J].
Aasland, R ;
Abrams, C ;
Ampe, C ;
Ball, LJ ;
Bedford, MT ;
Cesareni, G ;
Gimona, M ;
Hurley, JH ;
Jarchau, T ;
Lehto, VP ;
Lemmon, MA ;
Linding, R ;
Mayer, BJ ;
Nagai, M ;
Sudol, M ;
Walter, U ;
Winder, SJ .
FEBS LETTERS, 2002, 513 (01) :141-144
[2]   Suppressors of cytokine signalling (SOCS) in the immune system [J].
Alexander, WS .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (06) :410-416
[3]   The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immuneresponse [J].
Alexander, WS ;
Hilton, DJ .
ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 :503-529
[4]   Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel, p130(Cas)-related protein, Sin [J].
Alexandropoulos, K ;
Baltimore, D .
GENES & DEVELOPMENT, 1996, 10 (11) :1341-1355
[5]   The formation of a covalent complex between a dipeptide ligand and the src SH2 domain [J].
Alligood, KJ ;
Charifson, PS ;
Crosby, R ;
Consler, TG ;
Feldman, PL ;
Gampe, RT ;
Gilmer, TM ;
Jordan, SR ;
Milstead, MW ;
Mohr, C ;
Peel, MR ;
Rocque, W ;
Rodriguez, M ;
Rusnak, DW ;
Shewchuk, LM ;
Sternbach, DD .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (10) :1189-1194
[6]   TUMOR-INDUCTION BY ACTIVATED ABL INVOLVES TYROSINE PHOSPHORYLATION OF THE PRODUCT OF THE CBL ONCOGENE [J].
ANDONIOU, CE ;
THIEN, CBF ;
LANGDON, WY .
EMBO JOURNAL, 1994, 13 (19) :4515-4523
[7]   Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: Structural receptor requirements for signal attenuation [J].
Anhuf, D ;
Weissenbach, M ;
Schmitz, J ;
Sobota, R ;
Hermanns, HM ;
Radtke, S ;
Linnemann, S ;
Behrmann, I ;
Heinrich, PC ;
Schaper, F .
JOURNAL OF IMMUNOLOGY, 2000, 165 (05) :2535-2543
[8]   A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis [J].
Atsumi, T ;
Ishihara, K ;
Kamimura, D ;
Ikushima, H ;
Ohtani, T ;
Hirota, S ;
Kobayashi, H ;
Park, SJ ;
Saeki, Y ;
Kitamura, Y ;
Hirano, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (07) :979-990
[9]  
Aversa G, 1997, J IMMUNOL, V158, P4036
[10]   PHOSPHATIDYLINOSITOL 3'-KINASE IS ACTIVATED BY ASSOCIATION WITH IRS-1 DURING INSULIN STIMULATION [J].
BACKER, JM ;
MYERS, MG ;
SHOELSON, SE ;
CHIN, DJ ;
SUN, XJ ;
MIRALPEIX, M ;
HU, P ;
MARGOLIS, B ;
SKOLNIK, EY ;
SCHLESSINGER, J ;
WHITE, MF .
EMBO JOURNAL, 1992, 11 (09) :3469-3479